Literature DB >> 21939943

Surgical candidacy and selection biases in nonemergent left main stenting: implications for observational studies.

Edward J McNulty1, William Ng, John A Spertus, Jonathan G Zaroff, Robert W Yeh, Xiushi M Ren, Robert J Lundstrom.   

Abstract

OBJECTIVES: This study sought to characterize reasons for surgical ineligibility in patients undergoing nonemergent unprotected left main (ULM) percutaneous coronary intervention (PCI) and to assess the potential for these reasons to confound comparative effectiveness studies of coronary revascularization.
BACKGROUND: Although both PCI and coronary artery bypass graft surgery are treatments for ULM disease, some patients are not eligible for both treatments, which may result in treatment selection biases.
METHODS: In 101 consecutive patients undergoing nonemergent ULM PCI, mixed methods were used to determine the prevalence of treatment selection dictated by surgical ineligibility and to identify the reasons cited for avoiding coronary artery bypass graft surgery. We then determined whether these reasons were captured by the ACC-NCDR (American College of Cardiology-National Cardiovascular Data Registry) Cath-PCI dataset to assess the ability of this registry to account for biases in treatment selection. Finally, the association of surgical eligibility with long-term outcomes after ULM PCI was assessed.
RESULTS: Treatment selection was dictated by surgical ineligibility in over half the ULM PCI cohort with the majority having reasons for ineligibility not captured by the ACC-NCDR. Surgical ineligibility was a significant predictor of mortality after adjustment for Society of Thoracic Surgeons (hazard ratio [HR]: 5.4, 95% confidence interval [CI]: 1.2 to 25), EuroSCORE (European System for Cardiac Operative Risk Evaluation) (HR: 5.9, 95% CI: 1.3 to 27), or NCDR mortality scores (HR: 6.2, 95% CI: 1.4 to 27).
CONCLUSIONS: Surgical ineligibility dictating treatment selection is common in patients undergoing nonemergent ULM PCI, occurs on the basis of risk factors not captured by the ACC-NCDR, and is independently associated with worse long-term outcomes after adjusting for standard risk scores.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21939943     DOI: 10.1016/j.jcin.2011.06.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  15 in total

1.  Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Stephen W Waldo; Eric A Secemsky; Cashel O'Brien; Kevin F Kennedy; Eugene Pomerantsev; Thoralf M Sundt; Edward J McNulty; Benjamin M Scirica; Robert W Yeh
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

2.  Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention for Unprotected Left Main Disease - A Review.

Authors:  Edward McNulty
Journal:  Interv Cardiol       Date:  2013-03

3.  Comparative effectiveness of revascularization strategies.

Authors:  William S Weintraub; Maria V Grau-Sepulveda; Jocelyn M Weiss; Sean M O'Brien; Eric D Peterson; Paul Kolm; Zugui Zhang; Lloyd W Klein; Richard E Shaw; Charles McKay; Laura L Ritzenthaler; Jeffrey J Popma; John C Messenger; David M Shahian; Frederick L Grover; John E Mayer; Cynthia M Shewan; Kirk N Garratt; Issam D Moussa; George D Dangas; Fred H Edwards
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

Review 4.  Challenges in Risk Adjustment for Hospital and Provider Outcomes Assessment.

Authors:  William S Weintraub; Kirk N Garratt
Journal:  Circulation       Date:  2017-01-24       Impact factor: 29.690

5.  Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative.

Authors:  Javier A Valle; Hector Tamez; J Dawn Abbott; Issam D Moussa; John C Messenger; Stephen W Waldo; Kevin F Kennedy; Frederick A Masoudi; Robert W Yeh
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

Review 6.  Frailty assessment in the cardiovascular care of older adults.

Authors:  Jonathan Afilalo; Karen P Alexander; Michael J Mack; Mathew S Maurer; Philip Green; Larry A Allen; Jeffrey J Popma; Luigi Ferrucci; Daniel E Forman
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

7.  Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention.

Authors:  Ajay J Kirtane; Darshan Doshi; Martin B Leon; John M Lasala; E Magnus Ohman; William W O'Neill; Adhir Shroff; Mauricio G Cohen; Igor F Palacios; Nirat Beohar; Nir Uriel; Navin K Kapur; Dimitri Karmpaliotis; William Lombardi; George D Dangas; Manish A Parikh; Gregg W Stone; Jeffrey W Moses
Journal:  Circulation       Date:  2016-08-02       Impact factor: 39.918

8.  Modified inflammation-based score as an independent malignant predictor in patients with pulmonary focal ground-glass opacity: a propensity score matching analysis.

Authors:  Long Jiang; Shanshan Jiang; Yongbin Lin; Han Yang; Zerui Zhao; Zehua Xie; Yaobin Lin; Hao Long
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

Review 9.  Renin-angiotensin system blockade for the risk of cancer and death.

Authors:  Jian Shen; Yan-Mei Huang; Min Wang; Xue-Zhi Hong; Xin-Nan Song; Xia Zou; Yan-Hong Pan; Wei Ling; Min-Hui Zhu; Xiao-Xi Zhang; Yi Sui; Hai-Lu Zhao
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-07-08       Impact factor: 1.636

10.  Acute pulmonary embolism following recent hospitalization or surgery.

Authors:  Colby Shanafelt; Rahul Aggarwal; Tyler Mehegan; Abby Pribish; Kevin Soriano; Andrew Dicks; Eric A Secemsky; Brett J Carroll
Journal:  J Thromb Thrombolysis       Date:  2020-11-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.